

AION Diagnostics completes spin out

AION Diagnostics Inc is pleased to announce the completion of its successful spin-out from parent company pSivida Ltd.

The successful spin-out was completed in conjunction with AION's corporate advisor, New York based buyout specialist Global Emerging Markets (GEM). Following the spin-out AION's executive management team retain a 39% shareholding in the Company, GEM a major shareholder at 27% and following a private placement of new shares, outside investors represent the remaining 34% interest. Following the spin-out AION now has 13.14 million shares on issue.

AION Diagnostics Inc CEO Dr Anna Kluczevska said, "We are very pleased to have now completed the spin-out. This represents an exciting period in the growth of the Company. We look forward to continuing the development of AION's imaging products with European support for global innovation and advancement. "

- ENDS -

Released by:

AION Diagnostics

Alexandra Brown

Ph: +61 (8) 6461 9400

alexandra_brown@aiondiagnostics.com

European Public Relations

Eva Reuter

Ph: +49 (254) 393 0740

e.reuter@e-reuter-ir.com

NOTES TO EDITORS:

AION Diagnostics (AION) is a global biotechnology company dedicated to the commercialization of medical imaging contrast and molecular imaging agents for early stage detection of critical diseases. Founded in 2004, AION secured strategic alliances with universities, research institutions and industry partners internationally.

Exploiting the 10-year history of discoveries of porous silicon made by Professor Leigh Canham at the former UK Defence Evaluation Agency (now QinetiQ) and backed by USD\$50 million in cumulative previous investment in the technology, AION have developed mpSi which has been proven visible across all major imaging modalities. AION is leveraging the unique visualization capabilities of the mpSi technology platform with its biodegradable and biocompatible properties to produce imaging product divisions in Marking, Contrast and Molecular Imaging Agents. Additionally, one such strategic objective is the development of collaborations incorporating the mpSi platform with other materials to create superior versions of existing products.

Continuing to strive for better solutions to unmet diagnostic needs, AION's products are committed to the timely visualization of pathologies in a manner which may facilitate prevention rather than treatment of disease.